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a  b  s  t  r  a  c  t
Hepatitis  B virus  (HBV)  is  hyperendemic  to southern  Africa,  with  genotype  A of HBV  being  the  predomi-
nant  genotype,  and  subgenotype  A1 prevailing.  Infection  with  this  subgenotype  is associated  with  rapid
disease  progression,  and  high  frequency  of  hepatocellular  carcinoma  development.  The  objectives  of  our
study was  to construct  recombinant  1.28  mer  replication  competent  HBV  DNA  plasmids  of subgenotypes
A1,  A2  and  D3  containing  authentic  endogenous  HBV  promoters  and  to  follow  their  replication  in vitro
after  transfection  of  Huh7  cells.  We  found  that  subgenotype  D3 replicated  at a lower  level,  as  measured  by
HBsAg  and HBV  DNA  levels,  when  compared  to  cells  transfected  with  genotype  A. There  was  no difference
in  the  intracellular  and extracellular  HBsAg  between  cells  transfected  with  subgenotypes  A1 or  A2. Cellsransfection transfected  with  subgenotype  A1  had  higher  levels  of  intracellular  replicative  intermediates  and  HBcAg,
and  lower  extracellular  expression  of HBeAg  from  days  1  to 3, when  compared  to  cells  transfected  with
subgenotype  A2.  In conclusion,  the  generation  of these  replication  competent  clones  is  an  important  step
in  the functional  characterization  of  subgenotypes  of HBV  circulating  in Africa  and  their  comparison  to
strains  circulating  in other geographical  regions  of  the  world.
©  2014  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Hepatitis B virus (HBV) is the prototype member of the family
epadnaviridae, whose members consist of small enveloped DNA
iruses (Marion and Robinson, 1983). An unique feature of hepad-
aviruses is their unusual mechanism of DNA replication, which
nvolves reverse transcription of the pregenomic RNA (pgRNA) by
he viral polymerase/reverse transcriptase that lacks proofread-
ng activity (Summers and Mason, 1982). This has led to its high
equence heterogeneity and classiﬁcation into nine genotypes, A–I,
nd in the case of genotypes A–D, F and I, further into subgeno-
ypes (Arankalle et al., 2010; Arauz-Ruiz et al., 2002; Chu et al.,
003; Kramvis et al., 2008; Norder et al., 2004, 1992; Okamoto et al.,
988; Olinger et al., 2008; Schaefer, 2007). A putative tenth geno-
ype, designated genotype J has been proposed (Tatematsu et al.,
009). Subgenotypes A1, A2 and D3 are the strains circulating in
∗ Corresponding author. Tel.: +27 0488 3100; fax: +27 086 529 6806.
E-mail address: Anna.Kramvis@wits.ac.za (A. Kramvis).
ttp://dx.doi.org/10.1016/j.jviromet.2014.03.015
166-0934/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
South Africa (Kramvis et al., 2005; Kramvis and Kew, 2007). Geno-
types/subgenotypes can affect the molecular characteristics of the
virus, clinical manifestation of HBV infection in hosts, and response
to antiviral therapies and vaccination (Kao et al., 2000; Kramvis and
Kew, 2005).
In order to characterize functionally the geno-
types/subgenotypes of the virus, in vitro systems are necessary.
Although, HBV can infect cultured primary human hepatocytes
(PHH) (Galle et al., 1994; Gripon et al., 1993), the use of PHH cells
is limited by their variable quality and short-term viability (Galle
et al., 1994; Gripon et al., 1993, 1988; Mabit et al., 1996). Therefore,
currently in vitro systems used most frequently, include hepatoma
cell lines such as HepG2 and Huh7, which can be transfected with
replication competent cloned HBV DNA and subsequently produce
infectious and subviral particles (Durantel et al., 2004; Junker et al.,
1987; Sells et al., 1987; Sureau et al., 1988; Yaginuma et al., 1987).HBV consists of four partially overlapping open reading frames
(ORFs) (Ganem and Varmus, 1987; Robinson, 1990; Tiollais et al.,
1985). Therefore, linearization at any position of the HBV genome
results in the disruption of at least one ORF, which limits the
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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trategies for directly generating functional HBV isolates through
loning into conventional vectors (Yang et al., 2004). Therefore,
s an alternative, HBV DNA plasmids containing recombinant
ultimeric or terminally greater-than-genome length HBV DNA
enomes are used. Following transfection, from these HBV DNA
ontaining plasmids, all HBV components can be expressed, which
llows for virus propagation including virion and subviral particle
ormation that are morphologically and virologically indistinguish-
ble from the authentic viral particle (Durantel et al., 2004; Guha
t al., 2004; Guidotti et al., 1995; Sureau et al., 1988; Zoulim, 2006).
Most strategies for the synthesis of greater-than-genome length
BV DNA plasmids involve the use of vectors that contain a strong
xogenous promoter such as the cytomegalovirus (CMV) promoter.
u et al. (2009) have suggested that when these clones are trans-
ected in vitro, the CMV  promoter may  affect HBV gene expression
r replication, and a longer mRNA may  be transcribed, in addi-
ion to the normal pgRNA and precore mRNA. However, this longer
RNA may  not be packaged into the nucleocapsid because of the
iscrimination mechanism, which occurs when the translating 80S
ibosome enters the encapsidation signal area and terminates its
unctionality (Nassal et al., 1990). This does not happen for the
gRNA as the ﬁrst translation initiation codon is downstream of
he encapsidation signal.
Therefore, in order to study and compare the HBV strains circu-
ating in southern Africa, the objectives of the study were to:
1) Design a strategy that would allow for the construction
of recombinant 1.28 mer  replication competent plasmids of
subgenotype A1, A2 and D3 containing authentic endogenous
HBV promoters,
2) To compare the replication capacity of subgenotype D3 when
expressed from an authentic endogenous HBV promoter versus
an exogenous CMV  promoter, and
3) To compare the replication capacity of subgenotypes A1, A2 and
D3 in the absence of an exogenous promoter.
. Materials and methods
.1. Patient selection and ethics
Serum samples were collected from three asymptomatic carri-
rs of the virus (two from South Africa and one from Belgium) and
tored at −70 ◦C until further use. The full-length HBV DNA was
mpliﬁed using modiﬁed P1 and P2 primers as described previously
Gunther et al., 1995; Vermeulen et al., 2012). The strains isolated
rom South Africa belonged to subgenotypes A1 and D3, respec-
ively and that from Belgium to subgenotype A2. Ethics approval
o perform this study was obtained from the University of the Wit-
atersrand Research Ethics Committee (Medical), Johannesburg,
outh Africa.
.2. Construction of 1.28 mer  HBV DNA plasmids
The strategy used for the generation of recombinant 1.28 mer
reater-than-genome length HBV DNA plasmids is illustrated in
ig. 1.
.2.1. STEP 1: generation of HBV DNA circles and linear polymers
.2.1.1. Preparation of plasmids containing full-length HBV DNA. The
emplate plasmids consisting of full-length HBV DNA in pCR®-XL-
OPO® cloning vector (Invitrogen by Life Technologies Corporation,
arlsbad, USA) were prepared on a small scale using the Plasmid
NA Puriﬁcation NucleoSpin® Plasmid (Macherey-Nagel, Düren,
ermany). In order to conﬁrm the correct orientation and integrity
f the 5′- and 3′-ends of these plasmids, four independent diges-
ions were performed using: EcoRI; a combination of NcoI and NotI;cal Methods 203 (2014) 54–64 55
a combination of NcoI and FastDigest® SspI; and XhoI (Fermentas
Molecular Biology Tools by Thermo Fisher Scientiﬁc, Waltham,
USA). The ends of the inserts were sequenced using M13F-20 and
M13-R sequencing primers (Table 1) at Euroﬁns MWG  Operon
(Ebersberg, Germany). Extensive bioinformatics analyses showed
that the template plasmids, belonging to subgenotypes A1, A2
and D3, were not divergent from the consensus sequence of their
respective subgenotype. Thereafter, the plasmids were extracted
on a large scale using the Plasmid DNA Puriﬁcation NucleoBond®
PC 500 (Macherey-Nagel).
2.2.1.2. Synthesis of full-length HBV DNA circles and linear polymers.
In order to modify the orientation of the full-length HBV DNA in
the template plasmids, the full-length HBV DNA was ampliﬁed as
described in Table 2 using the Pwo Master (Roche Diagnostics by
Roche Applied Science, Mannheim, Germany) and the modiﬁed P1
and P2 primers containing SapI recognition sites in a MyCycler ther-
mal  cycler (Bio-Rad Laboratories, Hercules, USA). This ampliﬁcation
resulted in the generation of a full-length HBV DNA PCR product
containing SapI recognition sites on both 5′- and 3′-ends. The PCR
product was gel puriﬁed with Zymoclean Gel DNA Recovery KitTM
(Zymo Research, Irvine, USA) and digested with SapI  (Fermentas
Molecular Biology Tools). Digested PCR product was puriﬁed using
salt-ethanol precipitation and ligated to form full-length HBV DNA
circles and linear polymers using the Rapid DNA Dephos & Ligation
Kit (Roche Diagnostics). Thereafter, the full-length HBV DNA  circles
and linear polymers were further puriﬁed using salt-ethanol pre-
cipitation in order to be used as templates for the generation of NsiI
full-length HBV DNA and NsiI-BglII HBV DNA fragment.
2.2.2. STEP 2: generation of NsiI full-length HBV  DNA
2.2.2.1. Preparation of vector for NsiI full-length HBV DNA cloning.
The pGBKT7 cloning vector (Clonetech Laboratories, a Takara Bio
Company, Mountain View, USA) contains one NsiI  recognition site
and is ideal for use in the large scale propagation of NsiI  full-length
HBV DNA. This cloning vector was extracted on a large scale and
prepared for cloning by digestion with NsiI  (Fermentas Molecular
Biology Tools); gel puriﬁed and dephosphorylated using Alkaline
Phosphatase, Shrimp (Roche Diagnostics).
2.2.2.2. Synthesis of NsiI full-length HBV DNA. One NsiI recognition
site is found at position 1068 (when numbered from the EcoRI
recognition site (Galibert et al., 1979)) for subgenotypes A1, A2 and
D3. Using NsiI FL F and NsiI FL R primers containing NsiI  recogni-
tion sites, full-length HBV DNA was  ampliﬁed from the full-length
HBV DNA circles and linear polymers (Table 2). This ampliﬁcation
resulted in the addition of NsiI  recognition sites on both the 5′-
and 3′-ends of the PCR product. The PCR product was gel puriﬁed,
digested with NsiI, puriﬁed using salt–ethanol precipitation and
subsequently ligated to dephosphorylated NsiI  digested pGBKT7
cloning vector using the Rapid DNA Dephos & Ligation Kit. The
resultant plasmid constructs were transformed and propagated in
One Shot® TOP10 chemically competent Escherichia coli cells (Invi-
trogen). This plasmid DNA was extracted on a small scale and the
presence of NsiI full-length HBV DNA was  conﬁrmed by digestion
with NsiI. Thereafter, the plasmids were extracted on a large scale
and digested with NsiI to generate a large quantity of NsiI  full-
length HBV DNA, which was subsequently used in the downstream
generation of the 1.28 mer  HBV DNA plasmid.
2.2.2.3. Generation of NsiI full-length HBV DNA for wild-type subgeno-
type A1. Because the subgenotype A1 clone used as the template
for the generation of NsiI full-length clone contained the G1862T
mutation, this mutation was  reverted to the wild-type 1862G using
site-directed mutagenesis. As described in Table 2, this was done
using Platinum Taq DNA Polymerase High Fidelity (Invitrogen) and
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Fig. 1. Strategy for the generation of recombinant 1.28 mer  HBV DNA plasmids.
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Table  1
List of sequencing primers used to determine sequences of HBV clones.
Primer name Primer sequence Primer target Primer binding site
M13-F1 5′-GTA AAA CGA CGG CCA G-3′ pCR®-XL-TOPO® Cloning Vector 433–448
M13R-201 5′-CAG GAA ACA GCT ATA AC-3′ pCR®-XL-TOPO® Cloning Vector 205–211
Post-BglIIR  5′-CCG ATA CAG AGC TGA GGC-3′ HBV 2036–2042
pCR-BGH3.1R2 5′-TAG AAG GCA CAG TCG AGC-3′ pCDNATM4/TO Expression Vector 1089–1106
2058F3 5′-CCT TAG AGT CTC CTG AGC AT-3′ HBV 2058–2077
2497R 5′-CAC CTT ATG AGT CCA AGG AA-3′ HBV 2497–2516
2497F3 5′-TTC CTT GGA CTC ATA AGG TG-3′ HBV 2497–2516
3188F3 5′-AGT CAG GAA GGC AGC CTA C-3′ HBV 3188–3206
591F3 5′-ATT GCA CCT GTA TTC CCA TCC-3′ HBV 591–611
1040F 5′-TGG TTA CCC TGC CTT AAT GCC TT-3′ HBV 1038–1060
1040F (D3) 5′-TGG TTA TCC TGC TTT AAT GCC TT-3′ HBV 1038–1060
TO-F  5′-GGT TCC GCG CAC ATT TCC-3′ pCDNATM4/TO Expression Vector 5039–5056
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ceferences: 1URL: http://tools.invitrogen.com/contents/sfs/vectors/pcrxltopo m
(Vermeulen et al., 2012).
he GeneTailorTM Site-Directed Mutagenesis System (Invitrogen).
his plasmid DNA was extracted on a small scale and the presence
f the NsiI  full-length HBV DNA was conﬁrmed through digestion
ith NsiI. Site-directed mutagenesis was conﬁrmed by sequencing
t the University of Stellenbosch (Stellenbosch, South Africa) using
he Post-BglII sequencing primer (Table 1). Subsequently, these
lasmids were extracted on a large scale and digested with NsiI
o generate a large quantity of wild-type subgenotype A1 NsiI full-
ength HBV DNA, which was subsequently used in the downstream
eneration of wild-type subgenotype A1 recombinant 1.28 mer
BV DNA plasmid.
.2.3. STEP 3: generation of NsiI-BglII HBV DNA fragment
Using NsiI Frag F and BglII Frag R primers that resulted in the
ddition of the NsiI and BglII recognition sites on the 5′- and 3′-ends,
 NsiI-BglII HBV DNA fragment was ampliﬁed from full-length HBV
NA circles and linear polymers for subgenotypes A2 and D3 and
siI full-length HBV DNA containing plasmid for subgenotype A1
Table 2). The PCR product was puriﬁed using salt-ethanol precip-
tation, digested with NsiI  and BglII (Fermentas Molecular Biology
ools) and puriﬁed using salt-ethanol precipitation in preparation
or the downstream generation of the 1.28 mer  HBV DNA plasmid.
.2.4. STEP 4: preparation of a promoterless expression vector
The pCDNATM4/TO mammalian expression vector (Invitrogen)
as chosen as the expression vector because it is able to be prop-
gated in both prokaryotic and eukaryotic cells. This expression
ector does not contain a NsiI  recognition site within its multiple
loning site (MCS), but it contains one PstI recognition site, which
orms a compatible end with NsiI. Two BglII recognition sites are
resent in this vector; one in the MCS  and one prior to the CMV
romoter. This expression vector was propagated on a large scale
nd subsequently digested with PstI  (Fermentas Molecular Biology
ools) and BglII in order to remove the CMV  promoter and thus
llow the expression of HBV by its own authentic promoter. There-
fter, the digested expression vector containing BglII and PstI  sticky
nds on its 5′- and 3′-ends was gel puriﬁed and dephosphorylated
o prevent its recircularization during the downstream cloning pro-
ess of the recombinant 1.28 mer  HBV DNA plasmid.
.2.5. STEP 5: generation of recombinant 1.28 mer HBV DNA
lasmid
Aliquots of 1 g NsiI  digested NsiI  full-length HBV DNA, 150 ng
siI and BglII digested NsiI-BglII HBV DNA fragment and 50 ng BglII
nd PstI  digested dephosphorylated pCDNATM4/TO expression vec-
or were ligated using T4 DNA ligase (Roche Diagnostics) at 4 ◦C
or 16 h. The entire ligation reaction was transformed in 500 l
ne Shot® TOP10 chemically competent E. coli cells. The proto-
ol, was as described by the manufacturer, with the followingf, 2URL: http://tools.invitrogen.com/contents/sfs/vectors/pcdna4to.pdf) and
modiﬁcations: 1.25 ml  super optimal broth with catabolite repres-
sion (S. O. C.) medium (Invitrogen); the bacteria centrifuged at the
end of the procedure to remove the additional supernatant and
the plates incubated at 30 ◦C for 16 h followed by incubation at
37 ◦C for 6 h. The resultant plasmid DNA was then extracted on a
small scale and the orientation and size of the plasmids determined
with four independent digestions using: BamHI; EcoNI; FastDigest®
SspI and XbaI (Fermentas Molecular Biology Tools). The sequencing
reactions were performed using the following sequencing primers:
pCR-BGH3.1R, Post-BglII, 2058F, 2497F, 2497R, 3188F, 591F, 1040F
or 1040F (D3) and TO-F (Table 1) to conﬁrm the sequence of the
recombinant 1.28 mer  HBV DNA plasmid. After sequence conﬁrma-
tion, these plasmids were extracted on a large-scale in preparation
for transfections.
2.3. Cell culture and transfection
The Huh7 cell line (Japan Health Science Research Resources
Bank, catalogue number JCRB0403) was maintained in complete
growth Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% (v/v) foetal bovine serum (FBS) (Gibco® by
Invitrogen), 1% (v/v) 100× 100 mM sodium pyruvate (Gibco®), 1%
(v/v) 100 mM MEM  non-essential amino acids (Gibco®) and 2% (v/v)
100× penicillin–streptomycin–glutamine (Gibco®) and incubated
at 37 ◦C in a humid incubator containing 5% CO2. These cells were
passaged every 2–3 days.
Twenty four hours prior to transfection, 6 × 105 Huh7 cells
were plated into each 6 cm culture dish (or 1.2 × 106 cells plated
into each 10 cm culture dish for Southern Blotting) and incubated
overnight at 37 ◦C in a humidiﬁed incubator containing 5% CO2.
On the next day, one of the following: each of the recombinant
1.28 mer  HBV DNA plasmids, the positive replication competent
plasmid containing an exogenous CMV  promoter and eGFP plasmid
were transfected separately into Huh7 cells using the TransIT®-LT1
Transfection Reagent (Mirus Bio, Madison, USA), in triplicate and
incubated at 37 ◦C in a humidiﬁed incubator containing 5% CO2. The
supernatant was collected and replaced with new complete growth
medium on days 1 and 3 post-transfection and cells were harvested
on day 5 post-transfection. Transfection efﬁciency was measured 1
day post-transfection by determining the number of cells that had
been successfully transfected with eGFP using an Olympus IX71
ﬂuorescence microscope system (Olympus Soft Imaging Solutions,
Münster, Germany).
2.4. Expression of HBV DNA2.4.1. Expression of replicative intermediates
On day 5 post-transfection, total DNA (genomic, plasmid and
viral DNA) was  extracted from transfected Huh7 cells harvested
58
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Table 2
List of PCR primers and cycling conditions used for the generation of 1.28 mer  HBV DNA clones.
Primer name Primer sequence Primer binding site PCR cycling conditions Size
Cycles Initial
denaturation
Denaturation Annealing Extension Final
extension
Generation of full-length HBV DNA circles and linear polymers
SapI P1 F (A1, A2 + D3)1 5′ − CCGGAAAGCTTGAGCTCTTCTTTTTCACCTCTGCCTAATCA − 3′ 1821–1841
30
95 ◦C for
5 min
95 ◦C for
1 min
56 ◦C for
1 min
72 ◦C for
3:30 min
72 ◦C for
10 min
3240 bp for A1 and
A2 and 3201 bp for
D3
SapI  P2 R (A1) 5′ − CCGGAAAGCTTGAGCTCTTCAAAAAGTTGCATGATGATGG − 3′ 1806
–1825SapI  P2 R (A2 + D3)1 5′ − CCGGAAAGCTTGAGCTCTTCAAAAAGTTGCATGGTGCTGG − 3′
Generation of NsiI full-length HBV DNA
NsiI  FL F (A1) 5′-CCTGCATTAATGCCTTTGTATGCATG-3′
1055
–1070
30
95 ◦C for
5 min
95 ◦C for
1 min
56 ◦C for
1 min
72 ◦C for
3:30 min
72 ◦C for
10 min
3226 bp for A1 and
A2 and 3187 bp for
D3
NsiI  FL F (A2) 5′-CC TGCCTTAA TGCC TTTGTATGCATG -3′
NsiI  FL F (D3) 5′-CCTGCTTTAATGCCCTTGTATGCATG-3′
NsiI  FL R (A1) 5′-GCC TGTTTCGCTT GTATACATGC-3′
1066
–1088NsiI  FL R (A2) 5′-GCC TGTTTAGCTT GTATACATGC-3′
NsiI  FL R (D3) 5′-GCCTGCTTAGATTGAATACATGC-3′
Generation of wild-type subgenotype A1 NsiI full-length HBV DNA
A1-WT F 5′-TCTCTTGTACATGTCCCACTGTTCAAGCCTCC-3′ 1842–1873
25
94 ◦C for
2 min
94 ◦C for
30 sec
55 ◦C for
30 sec
68 ◦C for
11 min
68 ◦C for
10 min
10,524 bp
A1-WT  R 5′-AGTGGGACATGTACAAGAGATGATTAGGCA-3′ 1832–1861
Generation of NsiI-BglII HBV DNA fragment
NsiI  Frag F (A1) 5′-GGGGGG ATGCATGTATACAA GCGAAA CAGG C-3′
1064
–1088
25
95 ◦C for
5 min
95 ◦C for
1 min
56 ◦C for
1 min
72 ◦C for
2 min
72 ◦C for
10 min
933 bp
NsiI  Frag F (A2) 5′-GGGGGG ATGCATGTATACAA GCTAAA CAGG C-3′
NsiI  Frag F (D3) 5′-GGGGGGATGCATGTATT CAA TCTAA GCAGG C-3′
BglII Frag R (A1) 5′-GGGGGG AGATC TCGG ACGGAAGGAAA GAA GTCAGAAGG C-3′ 1993
–2023BglII  Frag R (A2 + D3) 5′-GGGGGG AGATCTCTGACGGAAGGAAA GAA GTCAGAA  GG C-3′
Reference: 1(Gunther et al., 1995).
The underlined text represents the HindIII recognition site, the bold text highlighted represents the SapI recognition site, the double underlined text represents the SstI  recognition site, the zigzagged text represents the NsiI
restriction  enzyme recognition site (full restriction enzyme recognition site for forward primer, and in part for the reverse primer), the dashed underlined text represents the BglII restriction enzyme recognition site, the bold
underlined text represents the mutated point for the generation of wild-type subgenotype A1 and the italicized text represents the HBV DNA.
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sing the NucleoSpin® Tissue (Macherey-Nagel), digested with
indIII and NotI and puriﬁed using DNA Clean & ConcentratorTM-5
Zymo Research). The extraction included a proteinase K diges-
ion. Total DNA was separated on an 1.5% (w/v) agarose gel
nd replicative intermediates detected using digoxigenin (DIG)-
abelled full-length wild-type subgenotype D3 probe using DIG
NA labelling and detection system (Roche Diagnostics).
.4.2. Intracellular and extracellular quantiﬁcation of HBV DNA
An aliquot of 5 ml  of transfected medium collected on day 3
r 5 was centrifuged at 22,000 × g for 5 min  at 4 ◦C after which
 100 l aliquot was adjusted with 10 l 10× Incubation Buffer
Roche Diagnostics) and treated with 1 l 10 U/l  DNase I (Roche
iagnostics) and 10 l 100 mg/ml  RNase A (Fermentas Molecular
iology Tools) and incubated at 37 ◦C for 20 min. Subsequently, the
eaction was terminated by adding 5 l 0.2 M EDTA, pH 8.0 and
ncubation at 75 ◦C for 10 min. Thereafter, extracellular total DNA
nd intracellular total DNA was extracted using the NucleoSpin®
issue. PCR primers, HBV DNA F (5′-CGTGTGTCTTGGCCAAAATTCG-
′) and HBV DNA R (5′-CATCCAGCGATAACCAGGACAA-3′), which
overs positions 292–379 of the S gene when numbered from the
coRI site, with a FAM/NFQ labelled TaqMan® MGB  probe (5′-FAM-
CACTCACCAACCTCC-NFQ-3′) were used to quantify HBV DNA in
he ABI 7500 Real Time PCR system (Applied Biosystems by Life
echnologies) using the PCR thermal cycling conditions described
reviously (Viana et al., 2009).
A serial dilution of plasmid DNA containing a single genome
f subgenotype D3, ranging from 1 × 104 to 1 × 108 copies/ml, was
sed as template to generate the standard curve. The 2nd WHO
nternational Standard, Hepatitis B Virus DNA (National Institute
or Biological Standards and Controls (NIBSC), Hertfordshire, UK),
hich has a ﬁnal concentration of 1 × 106 IU/ml was used as the
ositive control and to calibrate the standard curve. The reliability
f the standard curve was determined by PCR and repeated three
imes prior to being used to quantify samples. The standard curve,
lank, positive and negative controls and samples were all tested
n duplicate. The measured IU/ml for each reaction was calculated
sing the cycle threshold (Ct) value of each PCR interpolated against
he linear regression of the standard curve. For each sample, the
uplicate average value was multiplied by 4.7 to convert from IU/ml
o copies/ml. The detection limit was found to be 1 × 102 copies/ml.
n order to ensure that the quantitative HBV DNA data was  not
nﬂuenced by plasmid DNA carry-over, plasmid DNA in each sam-
le was quantiﬁed using plasmid-speciﬁc primers, plasmid DNA
 (5′-GCCGGAAGCATAAAGTGTAAAGC-3′ and plasmid DNA R (5′-
CTGGCACGACAGGTTTC-3′), which covers positions 2982–3090 of
he pCDNA4/TO vector, with a FAM/NFQ labelled TaqMan® MGB
robe (5′-FAM-TTGCGCTCACTGCCC-NFQ-3′). We  found that the
NA carry over was negligible.
.5. Expression of HBV proteins
.5.1. Intracellular expression of HBV proteins
Transfected Huh7 cells that were harvested on day 5 were
ysed with 100 l SDS cell lysis buffer (50 mM Tris–HCl, pH 6.8, 2%
w/v) SDS and 10% (v/v) glycerol) supplemented with Complete,
DTA-free, Protease Inhibitor Cocktail Tablets (Roche Diagnos-
ics). Protein concentration was determined using the Pierce®
CA Protein Assay Kit (Pierce Biotechnology by Thermo Fisher
cientiﬁc) and subsequently aliquots of 10 g of protein samples
nd Precision Plus ProteinTM WesternCTM Standards (Bio-Rad
aboratories) were separated on a 0.1% (w/v) SDS-12% (w/v)
olyacrylamide gel and transferred to nitrocellulose membranes.
he nitrocellulose membranes were blocked at room temperature
ith 5% (w/v) fat-free milk powder in Tris-buffered saline-Tweencal Methods 203 (2014) 54–64 59
(TBS-T) buffer (Blocking Solution). The nitrocellulose membranes
were incubated overnight at 4 ◦C with one of the following pri-
mary antibodies diluted in 5% (w/v) Blocking Solution: 1:50,000
mouse monoclonal antibody against -tubulin (clone B-5-1-2)
(Sigma–Aldrich, Saint Louis, USA), 1:25,000 rabbit polyclonal
antibody against GFP (ab6556) (Abcam, Cambridge, USA), 1:4000
mouse monoclonal antibody against the preS1 region of HBsAg
(MA18/7), 1:1000 mouse monoclonal antibody against the preS2
region of HBsAg (Q19/10) (both kindly donated by Dr. Dieter Glebe,
Justus-Liebig University, Giessen, Germany), 1:1000 mouse mon-
oclonal antibody cross-reacting against HBcAg and HBeAg (ID8)
(kindly donated by Dr. Peter Revill, Victorian Infectious Diseases
Reference Laboratory, Melbourne, Australia), respectively. The
nitrocellulose membranes were washed three times for 10 min,
respectively, with TBS-T and incubated at room temperature for
1 h with either 1:3000 goat anti-mouse IgG (H + L)-HRP conjugate
(Bio-Rad Laboratories)- or 1:3000 goat anti-rabbit IgG (H + L)-HRP
conjugate (Bio-Rad Laboratories)-containing 1:10,000 Precision
ProteinTM StrepTactin-HRP conjugate (Bio-Rad Laboratories) and
washed three times for 10 min, respectively, with TBS-T. The
protein signal of interest was  developed with the SuperSignal®
West Dura Extended Duration Substrate (Pierce Biotechnology)
after which the membranes were stripped with Blocking Solution
supplemented with 0.2% (w/v) sodium azide at room temperature
for 1 h.
2.5.2. Extracellular HBV proteins
The amount of extracellular HBsAg and HBeAg was determined
over a short time-course on days 1, 3 and 5 by enzyme-linked
immunosorbent assay (ELISA) using the MonolisaTM HBsAg ULTRA
(Bio-Rad Laboratories, Manes-la-Coquette, France) and MonolisaTM
HBeAg-Ab PLUS (Bio-Rad Laboratories), respectively.
2.6. Statistical analysis
Quantiﬁcation of HBV DNA and extracellular expression of
HBsAg and HBeAg was analyzed statistically using STATA® 12.0:
Data Analysis and Statistical Software (StataCorp, College Station,
USA). The signiﬁcance of differences observed between samples
was determined using the one-way ANOVA test and the Scheffe
comparison method. Probability (P) < 0.05 was regarded as statis-
tically signiﬁcant. Analysis was  obtained from three independent
transfection experiments performed in triplicate.
3. Results
3.1. Construction of recombinant 1.28 mer HBV DNA plasmids
Sequencing of the different HBV DNA inserts conﬁrmed the
presence of the distinctive sequence characteristics of the dif-
ferent subgenotypes (Fig. 2). Nucleotide divergence analysis
between the template and its corresponding 1.28 mer counterpart
showed low nucleotide divergence (<0.2%). The 1.28 mer  subgeno-
type D3 sequence inserted in the plasmid containing authentic
HBV promoters differed from the subgenotype D3 sequence
inserted in the plasmid driven by the exogenous CMV  promoter
by 1.82%.
3.2. Evidence for replication of the recombinant HBV DNA
genomes in plasmids3.2.1. Synthesis of replicative intermediates
Southern Blot analysis of HBV replicative intermediates was
used to determine the replication competence of newly generated
cloned 1.28 mer  HBV DNA genomes in comparison to the positive
60 N.H. Bhoola et al. / Journal of Virological Methods 203 (2014) 54–64
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ound  in the PreC region of subgenotype A1 have being highlighted (Baptista et al., 
ith  these same regions being highlighted in subgenotypes A2 and D3 to show diff
ontrol replication competent plasmid. The presence of relaxed cir-
ular, linear and very low concentrations of single-stranded DNA
n cells transfected with all four HBV DNA genome containing plas-
ids, but not in the control transfected cells, indicated that these
BV genomes were replication competent and produced replica-
ive intermediates (Fig. 3(A)). Cells transfected with HBV genome
3 (Exo) appeared to produce higher levels of replicative interme-
iates relative to cells transfected with HBV genome D3 (Fig. 3(A)).
oreover, the relative levels of the replicative intermediates were
ighest for cells transfected with HBV genome A1 and decreased
onsecutively for cells transfected with HBV genomes A2 and D3
Fig. 3(A)).
.2.2. Intracellular and extracellular quantiﬁcation of HBV DNA
From days 3 to 5, the only statistically signiﬁcant increase in
xtracellular HBV DNA was  observed for cells transfected with HBV
enome A1 (P < 0.05, Fig. 3(B)). Cells transfected with HBV genome
3 (Exo) had a statistically signiﬁcant higher intracellular HBV DNA
evel on day 5 relative to cells transfected with HBV genome D3
P < 0.05, Fig. 3(C)), whereas this was not the case for extracellular
BV DNA (Fig. 3(B)). There was no statistically signiﬁcant differ-
nce in the intracellular HBV DNA levels between the different
ubgenotypes (Fig. 3(C)), whereas a statistically signiﬁcant higher
xtracellular HBV DNA level was observed on day 5 when cells
ransfected with HBV genome A1 was compared to cells transfected
ith either HBV genomes D3 or A2 (P < 0.05, Fig. 3(B)).
.3. Expression of HBV proteins
.3.1. Intracellular expression of HBV proteins
Cells transfected with HBV genome D3 (Exo) had an increased
xpression of HBsAg and HBcAg when compared to cells trans-
ected with HBV genome D3 (Fig. 4). No signiﬁcant difference in the
xpression of HBsAg was observed between cells transfected with
he different subgenotypes (Fig. 4). HBeAg expression was highest
or cells transfected with HBV genome A1 and decreased consec-
tively for cells transfected with HBV genomes A2 and D3 (Fig. 4).1.28 mer  greater-than-genome length plasmid. The unique sequence characteristics
 Bowyer et al., 1997; Kimbi et al., 2004; Kramvis et al., 2002; Sugauchi et al., 2004),
s to subgenotype A1.
Intracellular HBcAg and/or HBeAg expression was higher for cells
transfected with HBV genome A1, relative to cells transfected with
either HBV genomes A2 or D3, respectively (Fig. 4).
3.3.2. Extracellular expression of HBV proteins
Expression of HBsAg was  detected earlier than that of HBeAg
(Fig. 4(B) and (C)). From days 1 to 3, a statistically signiﬁcant
increase in the expression of HBsAg was observed for cells trans-
fected with all HBV genomes analyzed (P < 0.05, Fig. 4(B)). This
increase was maintained for cells transfected with HBV genome
D3 from days 3 to 5 but not for cells transfected with either HBV
genomes A1 or A2, which showed a statistically signiﬁcant decrease
in expression (P < 0.05, Fig. 4(B)). HBsAg was  not measured beyond
day 5 and thus we could not determine whether this decrease was
maintained or whether the difference was as a result of ﬂuctua-
tions of maximum levels of expression on days 3 and 5. From days
1 to 5, a statistically signiﬁcant increase in the HBeAg expression
was observed for cells transfected with all HBV genomes analyzed
(P < 0.05, Fig. 4(C)). Signiﬁcantly higher levels of HBsAg on days 1
and 3 and HBeAg on day 5 were expressed by cells transfected
with HBV genome D3 (Exo) compared to cells transfected with HBV
genome D3 (P < 0.05, Fig. 4(B and C)). Cells transfected with HBV
genome D3 expressed signiﬁcantly lower HBsAg levels relative to
cells transfected with either HBV genomes A1 on all days or A2 on
days 1 and 3 (P < 0.05, Fig. 4(B)). On all days cells transfected with
HBV genome D3 showed a statistically signiﬁcantly lower expres-
sion of HBeAg when compared to cells transfected with either HBV
genomes A1 or A2 (P < 0.05, Fig. 4(C)). Cells transfected with HBV
genome A1 had a statistically lower expression of HBeAg relative to
cells transfected with HBV genome A2 on day 3 (P < 0.05, Fig. 4(C)).
4. DiscussionA new strategy was  used to generate plasmid containing recom-
binant 1.28 mer  HBV DNA genomes belonging to A1, A2 and D3,
subgenotypes known to circulate in southern Africa (Fig. 1) (Kew,
1994; Kew et al., 2005; Kramvis et al., 1998). This strategy provided
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Fig. 3. Expression of HBV DNA. (A) Blot following Southern blotting, which showed the detection of the HBV replicative intermediates (relaxed-circular, linear and single-
stranded DNA) when Huh7 cells were transfected with the plasmid containing 1.28 mer  HBV DNA genomes and the positive control replication competent plasmid and
harvested on day 5 post-transfection. Comparison between samples was made by the ratio of replicative intermediates against the linear plasmid DNA. Real-time PCR was
done  to determine the extracellular HBV DNA levels on days 3 and 5 (B) and the intracellular HBV DNA level on day 5 (C) from total DNA extracted from Huh7 cells that
were  transfected with plasmid containing 1.28 mer  HBV DNA genomes and the positive control replication competent plasmid, with medium collected and cells harvested
on  the corresponding days. (D) Ratio of extracellular to intracellular HBV DNA. HBV DNA levels for all samples have been normalized to the expression of D3 HBV DNA
on  day 5. It should be noted that all values and calculations were done after subtraction of plasmid DNA levels. Statistically signiﬁcant changes (P < 0.05) between samples
for  extracellular and intracellular HBV DNA levels have been shown by corresponding coloured asterisks for samples that have been compared. Error bars represent a 5%
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everal advantages. Firstly, the use of a complete proofreading
olymerase in the multiple PCR reactions ensured that very few
CR errors were introduced (Hu et al., 2009; Yang et al., 2004),
s demonstrated by the low nucleotide divergence of less than
.2% between the template and the ﬁnal product and the reten-
ion of the distinctive sequence characteristics of the subgenotypes
Fig. 2). Secondly, although the puriﬁcation steps after each tech-
ique were labour intensive, they prevented carry-over of enzymes,
on-speciﬁc products and reaction reagents, which inhibit down-
tream reactions (Hu et al., 2009). Thirdly, the ampliﬁcation of
BV as a complete genome ensured ampliﬁcation of a single strain
nd that chimaeras were not formed during the generation of the
ecombinant 1.28 mer  HBV DNA genomes. Fourthly, the 1.28 mer
BV DNA genome was ligated to a mammalian expression vector
ontaining no exogenous promoter, which ensured that when pro-
ided with a suitable environment, expression of HBV would be
riven by its own endogenous promoters and enhancers. More-
ver, the use of plasmid DNA, instead of a linear DNA, is known
o increase transfection efﬁciency of condensed supercoiled plas-
id  DNA, which passes through a cell membrane in a process
f endocytosis much more easily than its linearized counterpart
Cherng et al., 1999; von Groll et al., 2006) and provides greater
tability, which prevents the plasmid DNA from being degraded by
ytosolic nucleases (Sun and Nassal, 2006). Finally, the advantage ofusing a mammalian expression vector containing the 1.28 mer HBV
DNA is that it can be used in the establishment of stable cell lines
that constitutively express HBV proteins without the need for fur-
ther manipulation. Establishing stable cell lines are advantageous
because all cells express HBV proteins and virus, thus providing
a constant supply of the virus and minimizing inter-experiment
variation (Sun and Nassal, 2006).
This strategy can be used to construct recombinant 1.28 mer
HBV DNA genomes for the majority of genotypes/subgenotypes of
HBV. The NsiI  recognition site between 1064 and 1069 is conserved
for 94.7% (230/243) of genotype A, 96.9% (595/614) of genotype B,
94.7% (744/786) of genotype C, 66.67% (222/333) of genotype D,
7.2% (13/180) of genotype E, 100% of genotype G and 5.3% (1/19)
of genotype H sequences, but is absent in genotype F. This means
that this strategy without modiﬁcation cannot be used for the gen-
eration of genotype F and for the majority of genotypes E and H
isolates because of an absence of a NsiI recognition site at this posi-
tion. However, with a few minor modiﬁcations the robustness of
this strategy is maintained for genotypes E, F and H.
Transfection of Huh7 cells with the newly generated 1.28 mer
HBV DNA genome containing plasmids demonstrated the repli-
cation competence by the presence of replicative intermedi-
ates. Moreover, these clones were able to support expres-
sion of intracellular and extracellular HBV DNA levels at
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Fig. 4. Expression of HBV proteins. (A) Immunoblot showing the intracellular expression of HBV proteins from Huh7 cells that were transfected with 1.28 mer HBV DNA
containing plasmids and the positive control replication competent plasmid and harvested on day 5 post-transfection. The immunoblot shows the expression of control
proteins, -tubulin and GFP and experimental proteins: HBsAg and HBcAg. -tubulin was detected by the binding of primary mouse monoclonal antibody against -tubulin.
GFP  was detected by the binding of primary rabbit polyclonal against GFP. HBsAg was detected by the binding of primary mouse monoclonal against the PreS1 or PreS2 regions,
respectively. HBcAg and HBeAg were detected by the binding of primary mouse monoclonal antibody cross-reacting against HBcAg and HBeAg. All primary antibodies were
detected  using either secondary goat anti-mouse IgG (H + L)-HRP antibody or goat anti-rabbit IgG (H + L)-HRP antibody. The Precision Plus Protein WesternCTM Standards
were  detected with the use of Precision ProteinTM StrepTactin-HRP conjugate. The expression of protein of interest was determined relative to that of -tubulin. To facilitate
analysis, results from one blot have been shown as two different blots. The extracellular expression of HBsAg (B) and HBeAg (C) was determined from Huh7 cells that were
transfected with 1.28 mer  HBV DNA containing plasmids and a positive control replication competent plasmid, with medium been collected every second day from days
1  to 5. (D) Ratio of HBeAg to HBsAg. The extracellular expression of HBsAg and HBeAg for each of the recombinant HBV DNA containing plasmids was normalized to the
expression of HBsAg and HBeAg for HBV genome D3 on day 5, respectively. Statistically signiﬁcant changes (P < 0.05) between samples for the extracellular expression of
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LBeAg and HBsAg have been shown by corresponding coloured asterisks for sample
08–109 genome copies/ml, which is comparable with the concen-
ration of HBV DNA found in the sera of chronically infected humans
Ranki et al., 1995). Transfection of Huh7 cells with these cloned
BV genomes led to the expression of intracellular HBcAg and
BsAg and extracellular HBeAg and HBsAg for a period of ﬁve days.
xtracellular expression of HBsAg was detected earlier than that of
he HBeAg, which is similar to the expression pattern seen during
cute HBV infection (Dunn et al., 2009; Hollinger and Liang, 2001).
Cells transfected with the plasmid containing an exogenous
MV promoter expressed higher levels of HBV DNA and proteins
ompared to cells transfected with the plasmids containing the
uthentic endogenous HBV promoter. Thus, in agreement with
ther studies, it is evident that the CMV  promoter functions as a
ighly robust and efﬁcient transcriptional regulatory element that
upports high levels of HBV replication compared to the authen-
ic endogenous HBV promoter (Boshart et al., 1985; McKnight and
jian, 1986; Xu et al., 2001; Yew et al., 1997). However, the use of an
xogenous CMV  promoter has a number of disadvantages. The use
f plasmid vectors containing a CMV  promoter is prone to inactiva-
ion over time in vivo (Guo et al., 1996; Harms and Splitter, 1995;
oser et al., 1996; Yew et al., 1997), as well as in the induction of an have been compared. Error bars represent a 5% difference from the absolute value.
adaptive or innate immune response leading to inﬂammation and
cellular toxicity (Loisel et al., 2001; Schaack et al., 2011; Schiedner
et al., 2002).
Furthermore, unlike the endogenous HBV promoter, the exoge-
nous CMV  promoter is not liver-speciﬁc (Hu et al., 2010a,b; Loser
et al., 1996; Sevarino et al., 1987). For these reasons, one has to be
careful when interpreting results from in vivo studies using exoge-
nous promoters and correlating them to in vitro studies. Thus, the
use of recombinant 1.28 mer  HBV DNA plasmids containing only
endogenous HBV promoters and enhancers, but none from other
viruses, provides the advantage for being able to be used in both
in vitro and in vivo studies and allowing for such studies to be
compared.
Cells transfected with subgenotype D3 replicated at a lower
level, relative to cells transfected with genotype A. In a clinical
setting, the lower levels of serum HBV DNA and HBsAg following
infection with subgenotype D3 has been attributed to alterations
in the reverse transcriptase domains (Chandra et al., 2009).
The study found no difference in intracellular and extracel-
lular HBsAg expression, when cells were transfected with either
subgenotypes A1 or A2. When comparing intracellular expression,
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ells transfected with subgenotype A1 expressed higher levels of
eplicative intermediates and HBcAg, relative to that of cells trans-
ected with subgenotype A2.
Extracellularly, the HBeAg levels expressed by cells transfected
ith subgenotype A1 were lower on days 1 and 3 and higher
n day 5 when compared to cells transfected with subgenotype
2. In a clinical setting, patients infected with subgenotype A1
ad signiﬁcantly lower serum HBV DNA levels compared to those
nfected with subgenotype A2 or genotype D, regardless of HBeAg
tatus (Guarnieri et al., 2006; Kramvis et al., 1997; Tanaka et al.,
004). When TCAT mutations between 1809 and 1812, which are
haracteristic of subgenotype A1, were introduced into subgeno-
ype A2, there was a signiﬁcant decrease in HBeAg translation
n transfected cells (Ahn et al., 2003; Baptista et al., 1999). The
ntracellular accumulation of replicative intermediates and HBcAg
een in subgenotype A1 may  play a role in inducing liver damage
Sugiyama et al., 2006) and may  account for the rapid disease pro-
ression and high rates for HCC seen in individuals infected with
his subgenotype (Kew, 1994; Kew et al., 2005; Kramvis et al., 1998).
In conclusion, in vitro transfection of Huh7 cells with the newly
enerated 1.28 mer  HBV DNA clones were replication competent.
he study demonstrated that the type of transcriptional promoter
nd the different genotypes/subgenotypes of HBV inﬂuence the
xpression of proteins in HBV transfection studies. Therefore, when
omparing the outcomes of various experiments these factors
hould be taken into consideration and the results interpreted
ith caution. The direct comparison of the present ﬁndings, to
hose of Sugiyama et al. (2006) is not strictly speaking possible
ecause of differences in the experimental design, including, the
ifferent strains compared, the greater-than-genome length clone,
nd time-span of the transfection. In the earlier study, 1.24 mer
reater-than-genome length clones and shorter time-span for the
ransfection were used and the subgenotype of D strain was not
peciﬁed (Sugiyama et al., 2006). In contrast, in this study, 1.28 mer
reater-than-genome length clones were used and transfected cells
hat were harvested 5 days post-transfection and medium collected
n days 1, 3 and 5 post-transfection. Moreover, in this study, all
he strains used were classiﬁed into their respective subgenotypes.
mportantly, replication competent clones were generated from
trains circulating in southern Africa. The generation of these clones
s an important step in the further functional characterization of
frican strains of HBV and their comparison to strains circulating
n other geographical regions of the world.
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